Balyasny Asset Management
AUPH icon

Balyasny Asset Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Balyasny Asset Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-130,000
Closed -$978K – 2769
2022
Q3 		$978K Buy
+130,000
New +$1.13M ﹤0.01% 1825

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Balyasny Asset Management's AUPH Position: Q4 2025 in Review

Balyasny Asset Management sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2025, closing a stake of 217,781 shares — an estimated $2.41M sold.

Balyasny Asset Management first reported a position in AUPH in Q1 2017 and held it in 16 quarters. The position peaked at $14.4M in Q1 2023. 255 funds tracked by Wall St. Rank hold AUPH as of Q4 2025.

  • Balyasny Asset Management reported no remaining Aurinia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 217,781 Aurinia Pharmaceuticals shares in Q4 2025, an estimated $2.41M.
  • Balyasny Asset Management first reported a position in Aurinia Pharmaceuticals in Q1 2017 and held it in 16 quarters.
  • Balyasny Asset Management's Aurinia Pharmaceuticals position peaked at $14.4M in Q1 2023.
  • 255 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.